Skinvisible, Inc. (SKVI) Targets Global Skincare Market Projected to Reach $135B by 2021
- Owns patented Invisicare® polymer delivery system, prescription and over-the-counter skincare products formulated with Invisicare
- Business model to grow globally by out-licensing its proprietary and patented product line
- Developed multiple cannabis-based products with CBD from imported hemp (non-psychoactive), and will continue to develop line utilizing CBD and THC from marijuana
Skinvisible, Inc. (OTCQB: SKVI) is targeting a global skincare market projected to reach $135 billion by 2021 (http://nnw.fm/61ruV). SKVI also sees a worldwide dermatology market now of $80 billion plus a $30 billion worldwide over-the-counter (OTC) market (http://nnw.fm/0NaOC). It has already completed on the development of 40 products, received numerous technology and product patents, and is now ready to monetize its investment. In the US alone, skincare is projected to reach $10.7 billion by 2018 and the global skincare market is seen growing at a compound annual growth rate (CAGR) of 3.8% from 2016-2021 according to MarketResearch.com (http://nnw.fm/3Uy9z).
It seeks to maximize profits on already-licensed products and grow by adding more licenses to established manufacturers and marketers. Skinvisible has recently formed commercial subsidiaries, Kintari International Inc., along with Kintari USA Inc. and Kintari Canada, Inc. It formed the subsidiaries to bring its cosmeceutical and select OTC products to market.
Skinvisible is a Nevada-based R&D company focused on the licensing of its topical formulations made with its proprietary polymer-based delivery technology Invisicare®. Invisicare is a technology with 14 international patents and is designed to improve the delivery of the active ingredients. Invisicare holds active ingredients on the skin for extended time periods and control their release.
Along with dermatology, the company has also seen a growing demand for topically-delivered cannabis. This is evidenced by its recent announcement with Canopy Growth Corporation in Canada.
The Company in a recent 10Q SEC filing (http://nnw.fm/76cxG) indicated it will continue to out-license its patented prescription and OTC products formulated with Invisicare. Its business model is to increase the value of its product pipeline, boost licensing revenues, capitalize on the success of current licensees, and generate revenue from online and retail sales of its cosmeceutical/OTC line.
The filing added that Skinvisible has named David St. James to the board of directors. An inventor and businessman based in Las Vegas, he is deemed qualified in recognition of his technical abilities and management skills.
For more information, visit the company’s website at www.Skinvisible.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Owns patented Invisicare® polymer delivery system, prescription and over-the-counter skincare products formulated with Invisicare
- Business model to grow globally by out-licensing its proprietary and patented product line
- Developed multiple cannabis-based products with CBD from imported hemp (non-psychoactive), and will continue to develop line utilizing CBD and THC from marijuana
Skinvisible, Inc. (OTCQB: SKVI) is targeting a global skincare market projected to reach $135 billion by 2021 (http://nnw.fm/61ruV). SKVI also sees a worldwide dermatology market now of $80 billion plus a $30 billion worldwide over-the-counter (OTC) market (http://nnw.fm/0NaOC). It has already completed on the development of 40 products, received numerous technology and product patents, and is now ready to monetize its investment. In the US alone, skincare is projected to reach $10.7 billion by 2018 and the global skincare market is seen growing at a compound annual growth rate (CAGR) of 3.8% from 2016-2021 according to MarketResearch.com (http://nnw.fm/3Uy9z).
It seeks to maximize profits on already-licensed products and grow by adding more licenses to established manufacturers and marketers. Skinvisible has recently formed commercial subsidiaries, Kintari International Inc., along with Kintari USA Inc. and Kintari Canada, Inc. It formed the subsidiaries to bring its cosmeceutical and select OTC products to market.
Skinvisible is a Nevada-based R&D company focused on the licensing of its topical formulations made with its proprietary polymer-based delivery technology Invisicare®. Invisicare is a technology with 14 international patents and is designed to improve the delivery of the active ingredients. Invisicare holds active ingredients on the skin for extended time periods and control their release.
Along with dermatology, the company has also seen a growing demand for topically-delivered cannabis. This is evidenced by its recent announcement with Canopy Growth Corporation in Canada.
The Company in a recent 10Q SEC filing (http://nnw.fm/76cxG) indicated it will continue to out-license its patented prescription and OTC products formulated with Invisicare. Its business model is to increase the value of its product pipeline, boost licensing revenues, capitalize on the success of current licensees, and generate revenue from online and retail sales of its cosmeceutical/OTC line.
The filing added that Skinvisible has named David St. James to the board of directors. An inventor and businessman based in Las Vegas, he is deemed qualified in recognition of his technical abilities and management skills.
For more information, visit the company’s website at www.Skinvisible.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
